Dr. Reddy’s Q3 & 9M FY24 Financial Results

Rhea-AI Summary

Dr. Reddy’s Laboratories Ltd. announced consolidated financial results for Q3FY24 and 9MFY24, with a 7% YoY revenue increase. The company reported a 58.5% gross margin for Q3FY24 and a 30.9% EBITDA margin for 9MFY24. Dr. Reddy’s Laboratories also highlighted key business developments and ESG achievements, positioning the company as a leader in the pharmaceutical industry.

Positive

• Consolidated revenue increased by 7% YoY for Q3FY24 and 14% for 9MFY24, driven by market share gains in North America and growth in Europe.
• Gross margin for Q3FY24 was 58.5%, down by 0.7% YoY, attributed to lower prices in generic markets, partially offset by an improved product mix and productivity.
• The EBITDA margin for 9MFY24 was 30.9%, showcasing a strong financial performance and operational efficiency.
• The company achieved several business milestones, including the acquisition of MenoLabs, an exclusive collaboration for ALS treatment, and successful inspections by the U.S. FDA.
• Dr. Reddy’s Laboratories was recognized for its commitment to ESG initiatives, being featured in the Dow Jones Sustainability World Index and receiving awards for Corporate Social Responsibility and Governance excellence.

Negative

• The effective tax rate for the quarter increased to 24.5% due to a higher proportion of profits from higher tax jurisdictions.
• QoQ decline in profit before tax and profit after tax for Q3FY24, indicating a potential slowdown in financial performance compared to the previous quarter.

Insights

Financial Analyst

An examination of Dr. Reddy's Laboratories Ltd.'s financial results for Q3 and the nine months ending December 31, 2023, reveals several key performance indicators crucial for investors and market analysts. The company's revenue has seen a year-over-year (YoY) increase of 7% in Q3 and 14% over the nine months, indicating a solid growth trajectory. This growth is particularly driven by market share gains in North America and Europe, which are significant markets for pharmaceutical companies. The reported gross margin, however, shows a slight decrease both YoY and quarter-over-quarter (QoQ), suggesting potential pressure on profitability.

SG&A expenses have risen by 12% YoY, which could be indicative of increased investment in marketing and sales efforts to capture market share. R&D expenditure remains consistent at 7.7% of revenues, emphasizing the company's commitment to innovation and future product pipelines. The EBITDA margin is relatively stable and the company maintains a healthy debt-to-equity ratio, indicating sound financial management. Investors should note the company's operational efficiency and robust free cash flow, despite a minor QoQ decrease in profit after tax, which could be attributed to higher tax rates in profitable jurisdictions.

Market Research Analyst

From a market perspective, Dr. Reddy's performance in various segments provides insights into the company's strategic positioning. The North American market, which showed a 9% YoY growth, is particularly noteworthy as it is a highly competitive and lucrative market for generic drugs. The company's ability to launch new products and gain market share here is a positive indicator of its competitiveness and regulatory prowess, given the stringent FDA requirements. Europe's 15% YoY growth, despite a QoQ decline, suggests effective market penetration and favorable currency movements, although price erosion remains a challenge.

Emerging markets present a mixed picture with a 2% YoY decline, yet a 6% QoQ growth, highlighting the volatility and currency risks in these regions. Dr. Reddy's strategic collaborations, such as the one with Coya Therapeutics and its focus on women's health supplements in the U.S., indicate targeted efforts to diversify and strengthen its portfolio in niche therapeutic areas. These strategic moves may enhance the company's long-term market position and mitigate risks associated with generic drug commoditization.

Medical Research Analyst

Dr. Reddy's investment in R&D, maintaining at 7.7% of revenues, is critical for sustaining long-term growth in the pharmaceutical industry, where innovation is a key differentiator. The company's focus on differentiated assets and the development of both small molecules and biosimilars aligns with industry trends towards personalized medicine and biologics. The ongoing clinical trials and the pipeline of new products could lead to future revenue streams and help the company maintain its competitive edge.

The regulatory landscape, as indicated by the U.S. FDA inspections and the issuance of Form 483s, is an important consideration for investors. While these observations can be a normal part of the regulatory process, the company's response and remediation efforts will be crucial in maintaining manufacturing credibility and avoiding potential market access delays. The company's inclusion in the Dow Jones Sustainability World Index and its ESG initiatives reflect a commitment to corporate responsibility, which is increasingly important to investors and may positively influence the company's reputation and stock valuation.

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).

		Q3FY24		9MFY24
Revenues		Rs. 72,148 Mn [Up: 7% YoY; Up: 5% QoQ]		Rs. 208,334 Mn [Up: 14% YoY; Up]
Gross Margin		58.5% [Q3FY23: 59.2%; Q2FY24: 58.7%]		58.6% [9M FY23: 56.5%]
SG&A Expenses		Rs. 20,228 Mn [Up: 12% YoY; 8% QoQ]		Rs. 56,725 Mn [Up: 13% YoY]
R&D Expenses		Rs. 5,565 Mn [7.7% of Revenues]		Rs. 15,996 Mn [7.7% of Revenues]
EBITDA		Rs. 21,107 Mn [29.3% of Revenues]		Rs. 64,278 Mn [30.9% of Revenues]
Profit before Tax		Rs. 18,257 Mn [Up: 12% YoY; Down: 5% QoQ]		Rs. 55,854 Mn [Up: 19% YoY]
Profit after Tax		Rs. 13,789 Mn [Up: 11% YoY; Down: 7% QoQ]		Rs. 42,614 Mn [Up: 20% YoY]

Commenting on the results, Co-Chairman & MD, G V Prasad said: “We delivered another quarter of highest-ever sales and robust financial performance aided by new products performance and base business market share gain in the U.S., new products launch momentum and strong performance in Europe. We continue to strengthen our core businesses and invest in innovative products including strategic collaborations for novel molecules to meet unmet needs of patients.”

All amounts in millions, except EPS
All US dollar amounts based on convenience translation rate of 1 USD = Rs. 83.19

Dr. Reddy’s Laboratories Limited & Subsidiaries

Revenue Mix by Segment [Q3FY24]
Particulars		Q3FY24		Q3FY23		YoY		Q2FY24		QoQ
		(Rs.)		(Rs.)		Gr %		(Rs.)		Gr%
Global Generics		63,095		59,241		7%		61,084		3%
North America		33,492		30,567		9%		31,700		5%
Europe		4,970		4,303		15%		5,286		-6%
India		11,800		11,274		5%		11,860		-1%
Emerging Markets		12,833		13,097		-2%		12,163		6%
Pharmaceutical Services and Active Ingredients (PSAI)		7,839		7,758		1%		7,034		11%
Others		1,214		701		73%		684		78%
Total		72,148		67,700		7%		68,802		5%

Revenue Mix by Segment [9M FY24]
Particulars		9MFY24		9MFY23		YoY
		(Rs.)		(Rs.)		Gr%
Global Generics		184,262		159,511		16%
North America		97,245		76,383		27%
Europe		15,326		12,644		21%
India		35,141		36,113^		-3%
Emerging Markets		36,550		34,371		6%
Pharmaceutical Services and Active Ingredients (PSAI)		21,582		21,282		1%
Others		2,490		2,119		18%
Total		208,334		182,911		14%
^ includes divestment income in India in Q1FY23, excluding which India YoY growth is at 4% and total company growth is at 15%

Consolidated Income Statement [Q3FY24]
Particulars		Q3FY24				Q3FY23				YoY		Q2FY24				QoQ
		($)		(Rs.)		($)		(Rs.)		Gr %		($)		(Rs.)		Gr%
Revenues		867		72,148		814		67,700		7		827		68,802		5
Cost of Revenues		360		29,945		332		27,607		8		342		28,434		5
Gross Profit		507		42,203		482		40,093		5		485		40,368		5
% of revenues				58.5%				59.2%						58.7%
Operating Expenses
Selling, General & Administrative expenses		243		20,228		216		17,981		12		226		18,795		8
% of revenues				28.0%				26.6%						27.3%
Research & Development expenses		67		5,565		58		4,821		15		65		5,447		2
% of revenues				7.7%				7.1%						7.9%
Impairment of non-current assets		1		110		2		134		(18)		1		55		100
Other operating (income)/expense		(12)		(967)		9		732		(232)		(22)		(1796)		(46)
Results from operating activities		208		17,267		197		16,425		5		215		17,867		(3)
Net finance (income)/expense		(12)		(963)		2		139		(793)		(15)		(1225)		(21)
Share of profit of equity accounted investees, net of tax		(0)		(27)		(1)		(60)		(55)		(1)		(42)		(36)
Profit before income tax		219		18,257		196		16,346		12		230		19,134		(5)
% of revenues				25.3%				24.1%						27.8%
Income tax expense		54		4,468		47		3875		15		52		4,334		3
Profit for the period		166		13,789		150		12,471		11		178		14,800		(7)
% of revenues				19.1%				18.4%						21.5%
Diluted Earnings Per Share (EPS)		0.99		82.68		0.90		74.95		10		1.07		88.78		(7)

EBITDA Computation [Q3FY24]						*Includes income from Investments
Particulars		Q3FY24				Q3FY23				Q2FY24
		($)		(Rs.)		($)		(Rs.)		($)		(Rs.)
Profit before Income Tax		219		18,257		196		16,346		230		19,134
Interest (income) / expense - Net*		(12)		(1,030)		(1)		(93)		(14)		(1,166)
Depreciation		29		2,437		27		2,245		29		2,437
Amortization		16		1,333		12		1,026		16		1,353
Impairment		1		110		2		134		1		55
EBITDA		254		21,107		236		19,658		262		21,813
% of revenues				29.3%				29.0%				31.7%

Consolidated Income Statement [9MFY24]
Particulars		9MFY24				9MFY23				YoY
		($)		(Rs.)		($)		(Rs.)		Gr %
Revenues		2,504		208,334		2,199		182,911		14
Cost of Revenues		1,036		86,210		956		79,565		8
Gross Profit		1,468		122,124		1,242		103,346		18
% of revenues				58.6%				56.5%
Operating Expenses
Selling, General & Administrative expenses		682		56,725		601		50,034		13
% of revenues				27.2%				27.4%
Research & Development expenses		192		15,996		168		14,015		14
% of revenues				7.7%				7.7%
Impairment of non-current assets		2		176		2		159		11
Other operating (income)/expense		(43)		(3,543)		(68)		(5,626)		(37)
Results from operating activities		634		52,770		538		44,764		18
Net finance (income)/expense		(36)		(2,972)		(25)		(2,054)		45
Share of profit of equity accounted investees		(1)		(112)		(4)		(294)		(62)
Profit before income tax		671		55,854		566		47,112		19
% of revenues				26.8%				25.8%
Income tax expense		159		13,240		140		11,637		14
Profit for the period		512		42,614		426		35,475		20
% of revenues				20.5%				19.4%
Diluted Earnings Per Share (EPS)		3.07		255.68		2.56		213.24		20

EBITDA Computation [9MFY24]		*Includes income from Investments
Particulars		9MFY24				9MFY23
		($)		(Rs.)		($)		(Rs.)
Profit before Income Tax		671		55,854		566		47,112
Interest (income) / expense - Net*		-35		-2,881		1		52
Depreciation		86		7,155		77		6,402
Amortization		48		3,974		37		3,045
Impairment		2		176		2		159
EBITDA		773		64,278		682		56,769
% of revenues				30.9%				31.0%

Key Balance Sheet Items
Particulars		As on 31st Dec 2023				As on 30th Sep 2023				As on 31st Dec 2022
		($)		(Rs.)		($)		(Rs.)		($)		(Rs.)
Cash and cash equivalents and other investments		922		76,665		839		69,784		603		50,164
Trade receivables		943		78,417		838		69,722		902		75,046
Inventories		731		60,796		680		56,592		593		49,326
Property, plant, and equipment		875		72,795		847		70,478		781		64,996
Goodwill and Other Intangible assets		495		41,192		496		41,278		426		35,401
Loans and borrowings (current & non-current)		239		19,851		159		13,230		212		17,663
Trade payables		374		31,113		366		30,485		313		26,023
Equity		3,220		267,850		3,042		253,086		2,648		220,273

Key Business Highlights [Q3FY24]

• Acquired the MenoLabs branded portfolio of women’s health focused supplements in the U.S.
• Exclusive collaboration with Coya Therapeutics for development and commercialization of COYA 302, an Investigational Combination Therapy for treatment of Amyotrophic Lateral Sclerosis (ALS)
• Inspections completed by U.S. FDA at Bachupally facility. The response to the observations were submitted within stipulated timelines.
  • Product specific Pre-Approval Inspection (PAI) at biologics manufacturing facility in October 2023, post which a Form 483 with 9 observations was issued,
  • Routine cGMP inspection at formulations manufacturing facility (FTO-3) in October 2023, post which a Form 483 with 10 observations was issued and
  • GMP and Pre-Approval Inspection (PAI) at R&D unit in December 2023, post which a Form 483 with 3 observations was issued.

ESG & other Highlights [Q3FY24]

• 1st Indian pharma company to be featured in the Dow Jones Sustainability World Index for 2023 and retaining our place in the Emerging Markets Index for the 8^th year in a row.
• Awarded ‘Gold Medal’ status by EcoVadis.
• MSCI ESG ratings upgraded from BB to BBB
• Awarded Golden Peacock awards for Corporate Social Responsibility, 2023 and Excellence in Corporate Governance, 2023
• Received ICSI Corporate Social Responsibility Excellence award - 2023, in recognition of our contribution to society through our CSR initiatives.
• 1^st Indian pharma company to pledge towards a plantation initiative covering 2,900 hectares by 2028 as part of the World Economic Forum’s 1t.org.

Revenue Analysis [Q3FY24]

• Q3FY24 consolidated revenue at Rs. 72.1 billion, YoY growth of 7% and QoQ growth of 5%. The YoY growth was primarily driven by market share gains for our existing products in North America and continuation of our growth journey in Europe.

Global Generics (GG)

• Q3FY24 revenue at Rs. 63.1 billion, YoY growth of 7% and QoQ growth of 3%. YoY growth was primarily driven by increase in volumes of our base business, new product launches, partially offset by price erosion in certain markets. Sequential growth was driven by increase in volumes of our base business, offset partially due to price erosion in certain markets.

North America

• Q3FY24 revenue at Rs. 33.5 billion, YoY growth of 9% and QoQ growth of 5%. YoY growth was on account of market share expansion in certain existing key products and revenues from new product launches, partly offset by price erosion. Sequential growth was driven by net increase in volumes of our base business.
• During the quarter, we launched 4 new products in the region, of which 2 were launched in the U.S.
• During the quarter, we filed 2 new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA). As of 31^st December 2023, cumulatively 79 generic filings are pending for approval with the USFDA (75 ANDAs and 4 NDAs under 505(b)(2) route). Out of the pending 79 generic filings, 41 are Para IVs, and we believe 21 have ‘First to File’ status.

Europe

• Q3FY24 revenue at Rs. 5.0 billion, YoY growth of 15% and QoQ decline of 6%. YoY growth was primarily on account of contribution from new product launches, improvement in base business volumes and favourable currency exchange rate movements, partly offset by price erosion. QoQ decline was primarily on account of price erosion in certain countries, partly offset by increase in volumes of our base business.
  • Germany at Rs. 2.7 billion, YoY growth of 21% and QoQ growth of 0.1%.
  • UK/OL at Rs. 1.4 billion, YoY growth of 9% and QoQ decline of 22%.
  • Rest of Europe at Rs. 0.9 billion, YoY growth of 11% and QoQ growth of 7%.
• During the quarter, we launched 6 new products in the region.

India

• Q3FY24 revenue at Rs. 11.8 billion, YoY growth of 5% and QoQ decline of 1%. YoY growth was largely attributable to revenues from new products launches while QoQ decline was largely on lower volumes in base business.
• During the quarter, we launched 3 new brands in the country.

Emerging Markets

• Q3FY24 revenue at Rs. 12.8 billion, YoY decline of 2% and QoQ growth of 6%. YoY decline is attributable to unfavorable forex movement, while QoQ growth was driven by volume gains for few existing products and partially offset by unfavorable currency exchange rate movements.
  • Revenue from Russia at Rs. 5.9 billion, YoY decline of 14% and QoQ growth of 2%.
    YoY decline was majorly due to unfavorable currency exchange rate movements & high base business.
    QoQ growth was largely on account of improved volumes and increase in certain brand prices, partially offset by unfavorable currency exchange rate movements.
  • Revenue from other CIS countries and Romania at Rs. 2.3 billion, YoY growth of 4% and QoQ growth of 7%.
    YoY growth was primarily on account of increase in price of certain brands, new product launches and favorable forex.
    QoQ growth was driven by increase in base business volumes and new launches.
  • Revenue from Rest of World (RoW) territories at Rs. 4.6 billion, YoY growth of 16% and QoQ growth of 10%.
    YoY growth was largely attributable to contribution from new products.
    QoQ growth was primarily driven by increase in base business volumes and new product launches.

Pharmaceutical Services and Active Ingredients (PSAI)

• Q3FY24 revenue at Rs. 7.8 billion, with a growth of 1% YoY and 11% QoQ. YoY growth was mainly driven by revenues from new products, favourable forex, partially offset by price decline and low business volumes. QoQ growth was driven by improved volumes in base business and contributions from new product launches. Excluding revenue in base period from COVID-19 products, PSAI business grew in double-digit.
• During the quarter, we filed 38 Drug Master Files (DMFs) globally.

Income Statement Highlights:

• Q3FY24 gross margin at 58.5% (GG: 61.9%, PSAI: 29.4%). Gross margin decreased by ~73 bps YoY and 18 bps sequentially. The decline in margin was primarily driven by lower prices for certain products in generic markets, partly offset by improvement in product mix and productivity.
• Selling, general & administrative (SG&A) expenses for Q3FY24 at Rs. 20.2 billion, YoY increase of 12% and by 8% QoQ. The YoY SG&A spend increase is largely on account of investments in sales & marketing activities, digitalization capabilities, and new business initiatives.
• Research & development (R&D) expenses in Q3FY24 at Rs. 5.6 billion. As % to Revenues – Q3FY24: 7.7% | Q2FY24: 7.9% | Q3FY23: 7.1%. R&D investments are driven by ongoing clinical trials on differentiated assets, as well as other developmental efforts to build a healthy pipeline of new products across our markets for both small molecules and biosimilars.
• Other operating income for Q3FY24 at Rs. 0.9 billion compared to other operating expenses of Rs. 0.7 billion in Q3FY23. Other operating income was largely on account of sale of non-current assets.
• Net Finance income for Q3FY24 at Rs.0.9 billion compared to net finance expense of Rs. 0.1 billion in Q3FY23. The higher income was primarily on account of profit on sale of units of mutual funds and other investments.
• Profit before Tax for Q3FY24 at Rs. 18.3 billion, YoY growth of 12%. QoQ decline of 5%.
• Profit after Tax for Q3FY24 at Rs. 13.8 billion, YoY growth of 11%. QoQ decline of 7%. The effective tax rate for the quarter has been 24.5% as compared to 23.7% in Q3FY23. The higher tax rate is mainly due to increase in the proportion of the Company's profits coming from higher tax jurisdictions, partly offset by adoption of corporate tax rate under section 115BAA of the Income Tax Act of India.
• Diluted earnings per share for Q3FY24 is Rs. 82.68

Other Highlights:

• EBITDA for Q3FY24 at Rs. 21.1 billion and the EBITDA margin is 29.3%.
• Operating Working Capital at Rs. 108.1 billion.
• Capital expenditure for Q3FY24 at Rs. 3.1 billion.
• Free cash-flow for Q3FY24 at Rs. 0.2 billion.
• Net cash surplus at Rs. 59.1 billion as on December 31, 2023.
• Debt to Equity is (0.21).
• ROCE for the company is 37% (annualized).

About key metrics and non-GAAP Financial Measures

This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.

All amounts in millions, except EPS

Reconciliation of GAAP measures to non-GAAP measures

Free Cash Flow
Particulars		Three months ended Dec. 31, 2023
		(Rs.)
Net cash generated from operating activities		10,762
Less:
Taxes		6027
Investments in PPE and Intangibles		4518
Free Cash Flow		217

Operating working capital
Particulars		As on 31st Dec 2023
		(Rs.)
Inventories		60,796
Trade Receivables		78,417
Less:
Trade Payables		31,113
Operating Working Capital		108,100

Net cash surplus
Particulars		As on 31st Dec 2023
		(Rs.)
Cash and cash equivalents		7,535
Investments		69,130
Short-term borrowings		(12,343)
Long-term borrowings, non-current		(6,152)
Less:
Restricted cash balance – Unclaimed dividend		122
Lease liabilities (included in Long-term borrowings, non-current)		(2,352)
Equity Investments (Included in Investments)		1328
Net Cash Surplus		59,072

Computation of Return on Capital Employed
Particulars		As on 31st Dec 2023
		(Rs.)
Profit before tax		18,257
Less:
Interest and Investment Income (Excluding forex gain/loss)		1,030
Earnings Before Interest and taxes [A]		17,227
Average Capital Employed [B]		191,125
Annualized Return on Capital Employed (A/B) (Ratio)		37%

Computation of capital employed
Particulars		Year Ended
		Dec 31, 2023		Mar 31, 2023
Property Plant and Equipment		72,795		66,462
Intangibles		36,905		30,849
Goodwill		4,287		4,245
Investment in equity accounted associates		4,218		4,702
Other Current Assets		23,512		20,069
Other investments		4,115		660
Other non-current assets		1,128		800
Inventories		60,796		48,670
Trade Receivables		78,417		72,485
Derivative Financial Instruments		-16		1,095
Less:
Other Liabilities		43,159		42,320
Provisions		5,394		5,513
Trade payables		31,113		26,444
Operating Capital Employed		206,491		175,760
Average Capital Employed		191,125

Computation of EBITDA

Refer page no. 3 & 4.

Earnings Call Details

The management of the Company will host an Earnings call to discuss the Company’s financial performance and answer any questions from the participants.

Date: January 30, 2024

Time: 19:30 pm IST | 10:00 am EDT

Conference Joining Information

Option 1: Pre-register with the below link and join without waiting for the operator

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1745002&linkSecurityString=a262ce748

Option 2: Join through below Dial-In Numbers
Universal Access Number:		+91 22 6280 1219 +91 22 7115 8120
International Toll-Free Number:		USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

Play Back: The play back will be available after the earnings call, till February 6^th, 2024. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 61003.

Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes no obligation to update any information contained herein.” The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131470785/en/

INVESTOR RELATIONS

RICHA PERIWAL

richaperiwal@drreddys.com

AISHWARYA SITHARAM

aishwaryasitharam@drreddys.com

MEDIA RELATIONS

USHA IYER

ushaiyer@drreddys.com

Source: Dr. Reddy’s Laboratories Ltd.

FAQ

What is Dr. Reddy's Laboratories' ticker symbol?

Dr. Reddy's Laboratories' ticker symbol is RDY.

What was the YoY revenue growth for Dr. Reddy's Laboratories in Q3FY24?

The YoY revenue growth for Dr. Reddy's Laboratories in Q3FY24 was 7%.

What was the EBITDA margin for Dr. Reddy's Laboratories in 9MFY24?

The EBITDA margin for Dr. Reddy's Laboratories in 9MFY24 was 30.9%.

What were the key business developments highlighted in the PR?

The key business developments included the acquisition of MenoLabs, an exclusive collaboration for ALS treatment, and successful inspections by the U.S. FDA.

What ESG achievements did Dr. Reddy's Laboratories highlight?

Dr. Reddy's Laboratories was featured in the Dow Jones Sustainability World Index, received awards for Corporate Social Responsibility and Governance excellence, and pledged towards a plantation initiative as part of the World Economic Forum's 1t.org.